Freddy Caldera1, Keith L Knutson2, Sumona Saha1, Arnold Wald1, Hiep S Phan3, Kelly Chun4, Ian Grimes1, Megan Lutz1, Mary S Hayney5, Francis A Farraye6. 1. Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA. 2. Department of Immunology, Mayo Clinic Jacksonville, Florida, USA. 3. Department of Medicine, Division of Internal Medicine, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA. 4. LabCorp, R&D and Specialty Medicine, Burlington, North Carolina, USA. 5. School of Pharmacy, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA. 6. Inflammatory Bowel Disease Center, Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
Abstract
INTRODUCTION: Patients with inflammatory bowel disease (IBD) on immune-modifying therapies may have a lower vaccine response to certain vaccines. The aim of our study was to evaluate humoral immunogenicity of mRNA coronavirus disease 2019 (COVID-19) vaccines among patients with IBD and healthy controls (HCs). METHODS: We performed a prospective study to evaluate humoral immunogenicity among patients with IBD and HCs after completion of mRNA COVID-19 vaccines. RESULTS: One hundred twenty-two patients with IBD and 60 HCs were enrolled. All HCs and 97% of patients with IBD developed antibodies. Antibody concentrations were lower in patients with IBD compared with those in HCs (median 31 vs 118 μg/mL; P < 0.001). Those who received the mRNA-1273 (Moderna) COVID-19 (median 38; interquartile range [IQR] 24-75 vs μg/mL) had higher antibody concentrations compared with those who received the Pfizer-BNT vaccine series (median 22; IQR 11-42 μg/mL; P < 0.001). Patients on immune-modifying therapy (median 26; IQR 13-50 μg/mL) had lower antibody concentrations compared with those who were on no treatment, aminosalicylates, or vedolizumab (median 59; IQR 31-75 μg/mL; P = 0.003). DISCUSSION: Almost all patients with IBD in our study mounted an antibody response. Future studies are needed in evaluating sustained humoral immunity and the impact of booster dosing in patients with IBD.
INTRODUCTION: Patients with inflammatory bowel disease (IBD) on immune-modifying therapies may have a lower vaccine response to certain vaccines. The aim of our study was to evaluate humoral immunogenicity of mRNA coronavirus disease 2019 (COVID-19) vaccines among patients with IBD and healthy controls (HCs). METHODS: We performed a prospective study to evaluate humoral immunogenicity among patients with IBD and HCs after completion of mRNA COVID-19 vaccines. RESULTS: One hundred twenty-two patients with IBD and 60 HCs were enrolled. All HCs and 97% of patients with IBD developed antibodies. Antibody concentrations were lower in patients with IBD compared with those in HCs (median 31 vs 118 μg/mL; P < 0.001). Those who received the mRNA-1273 (Moderna) COVID-19 (median 38; interquartile range [IQR] 24-75 vs μg/mL) had higher antibody concentrations compared with those who received the Pfizer-BNT vaccine series (median 22; IQR 11-42 μg/mL; P < 0.001). Patients on immune-modifying therapy (median 26; IQR 13-50 μg/mL) had lower antibody concentrations compared with those who were on no treatment, aminosalicylates, or vedolizumab (median 59; IQR 31-75 μg/mL; P = 0.003). DISCUSSION: Almost all patients with IBD in our study mounted an antibody response. Future studies are needed in evaluating sustained humoral immunity and the impact of booster dosing in patients with IBD.
Authors: Angelika Wagner; Erika Garner-Spitzer; Anna-Margarita Schötta; Maria Orola; Andrea Wessely; Ines Zwazl; Anna Ohradanova-Repic; Lukas Weseslindtner; Gabor Tajti; Laura Gebetsberger; Bernhard Kratzer; Elena Tomosel; Maximilian Kutschera; Selma Tobudic; Winfried F Pickl; Michael Kundi; Hannes Stockinger; Gottfried Novacek; Walter Reinisch; Christoph Zielinski; Ursula Wiedermann Journal: Front Immunol Date: 2022-05-12 Impact factor: 8.786
Authors: Trevor L Schell; Keith L Knutson; Sumona Saha; Arnold Wald; Hiep S Phan; Mazen Almasry; Kelly Chun; Ian Grimes; Megan Lutz; Mary S Hayney; Francis A Farraye; Freddy Caldera Journal: Inflamm Bowel Dis Date: 2022-04-09 Impact factor: 7.290
Authors: James L Alexander; Zhigang Liu; Diana Muñoz Sandoval; Catherine Reynolds; Hajir Ibraheim; Sulak Anandabaskaran; Aamir Saifuddin; Rocio Castro Seoane; Nikhil Anand; Rachel Nice; Claire Bewshea; Andrea D'Mello; Laura Constable; Gareth R Jones; Sharmili Balarajah; Francesca Fiorentino; Shaji Sebastian; Peter M Irving; Lucy C Hicks; Horace R T Williams; Alexandra J Kent; Rachel Linger; Miles Parkes; Klaartje Kok; Kamal V Patel; Julian P Teare; Daniel M Altmann; James R Goodhand; Ailsa L Hart; Charlie W Lees; Rosemary J Boyton; Nicholas A Kennedy; Tariq Ahmad; Nick Powell Journal: Lancet Gastroenterol Hepatol Date: 2022-09-09